VJHemOnc is committed to improving our service to you

EHA 2020 | Loncastuximab tesirine: a novel antibody-drug conjugate for DLBCL

VJHemOnc is committed to improving our service to you

Carmelo Carlo Stella

Carmelo Carlo Stella, MD, PhD, of Humanitas Clinical and Research Center, Rozzano, Italy, discusses initial results of a Phase II study of loncastuximab tesirine, a novel antibody-drug conjugate targeting CD19, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter